Tweenvest Stocks

PolyPid Ltd. (NasdaqCM: PYPD)

Health Care · Pharmaceuticals · IL

$5.11

+0.20% today · +47.8% 1Y

PolyPid Ltd. (NasdaqCM: PYPD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $103.59M and employs 72 people.

Over the last twelve months the share price has gained 47.8%, trading between 3.06 and 5.73.

Tweenvest scores PolyPid Ltd. across four factors: quality 25/100. Its strongest factor is quality.

PYPD price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$103.59M
Revenue (TTM)
P/E
EPS
-1.48
Dividend yield
Beta (5Y)
1.39
52-week high
$5.73
52-week low
$3.06
Avg volume (3M)
Shares outstanding
20.31M
Employees
72
Next earnings

About PolyPid Ltd.

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

ISIN
IL0011326795
Founded
2008
Listed since
Jun 26, 2020
Exchange
Nasdaq Capital Market
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.06T$1,189.41-3.59%
Johnson & JohnsonNYSE: JNJ$650.67B$270.00-1.15%
Merck & Co., Inc.NYSE: MRK$377.72B$153.10-2.14%
Roche Holding AGSWX: ROP$365.10BCHF368.30-1.47%
Novartis AGSWX: NOVN$300.07BCHF127.18-0.90%
AstraZeneca PLCLSE: AZN$257.89B£122.34-1.94%
Novo Nordisk A/SCPSE: NOVO B$210.23BDkr304.95-0.93%
Pfizer Inc.NYSE: PFE$161.30B$28.30-0.95%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.